RxDoctor Payments Data

Chad Ellis

Medical · Charlotte, NCNPI 1154889996

Payments from drug & device makers

$8,496in general payments, 2019–2025

Across 427 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$1K
  • AstraZeneca$760
  • GSK$652
  • Amgen$320
  • Novartis$300
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$8,38299%
  • Education$1001%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,496 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,386
Medicare patients
15
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala60$227,849
CabenuvaCabotegravir/Rilpivirine12$83,686
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$49,187
TrulicityDulaglutide13$11,390
Testosterone19$1,218
Fluoxetine Hcl27$592
Omeprazole61$548
Azelastine Hcl18$456
Celecoxib17$412
Atorvastatin Calcium76$408
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$329
Pregabalin13$289
Quetiapine Fumarate28$278
Losartan Potassium40$237
Amlodipine Besylate58$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$1,220$227,84960 claims
Viiv Healthcare CompanyCabenuva$1,361$83,68612 claims
Lilly USA, LLCTrulicity$258$11,39013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 medical providers in North Carolina.

Other medical in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →